Moomoo AIのまとめ
On September 16, 2024, ZyVersa Therapeutics, Inc. announced the entry into an At-The-Market (ATM) Sales Agreement with A.G.P./Alliance Global Partners. Under the agreement, ZyVersa may offer and sell shares of its common stock up to an aggregate offering price of $1,397,396. The sales will be conducted at prevailing market prices or as agreed with the Agent, who will receive a 3% commission on gross proceeds from any shares sold. The ATM Agreement allows for sales by any method deemed to be an 'at the market offering' as defined by law, with the amount and timing of sales determined by ZyVersa. There is no obligation for either party to sell or buy any shares, and no minimum offering amount is...Show More
On September 16, 2024, ZyVersa Therapeutics, Inc. announced the entry into an At-The-Market (ATM) Sales Agreement with A.G.P./Alliance Global Partners. Under the agreement, ZyVersa may offer and sell shares of its common stock up to an aggregate offering price of $1,397,396. The sales will be conducted at prevailing market prices or as agreed with the Agent, who will receive a 3% commission on gross proceeds from any shares sold. The ATM Agreement allows for sales by any method deemed to be an 'at the market offering' as defined by law, with the amount and timing of sales determined by ZyVersa. There is no obligation for either party to sell or buy any shares, and no minimum offering amount is required. The proceeds from any sales are intended for working capital and general corporate purposes, including administrative and R&D expenses. The offering of shares will be made under ZyVersa's shelf registration statement and prospectus filed with the SEC. The ATM Agreement includes customary representations, warranties, and covenants by ZyVersa, and it will terminate upon reaching the aggregate offering amount or earlier if conditions permit. The agreement also includes indemnification obligations for the Agent against certain liabilities.
2024年9月16日、ZyVersa Therapeutics, Inc.はA.G.P./Alliance Global Partnersとの段階的売買契約(At-The-Market, ATM)の締結を発表しました。この契約により、ZyVersaは普通株式を1,397,396ドルの総額で販売することができます。売買は市場価格または代理人との合意に基づいて行われ、代理人は売られた株式の総収益から3%の手数料を受け取ります。ATM契約により、法律で定義された段階的販売が行われ、販売の金額とタイミングはZyVersaが決定します。売買に関して当事者には買い付けや売り付けの義務はなく、最低販売金額も...すべて展開
2024年9月16日、ZyVersa Therapeutics, Inc.はA.G.P./Alliance Global Partnersとの段階的売買契約(At-The-Market, ATM)の締結を発表しました。この契約により、ZyVersaは普通株式を1,397,396ドルの総額で販売することができます。売買は市場価格または代理人との合意に基づいて行われ、代理人は売られた株式の総収益から3%の手数料を受け取ります。ATM契約により、法律で定義された段階的販売が行われ、販売の金額とタイミングはZyVersaが決定します。売買に関して当事者には買い付けや売り付けの義務はなく、最低販売金額も不要です。売上の収益は、運転資金、一般的な企業目的、および経理や研究開発費用を含む一般企業目的で使用される予定です。株式の募集は、ZyVersaの発行登録制度とSECに提出された目論見書に基づいて行われます。ATM契約にはZyVersaによる通常の表明、保証、および契約が含まれており、目標の募集金額の達成または条件が許す場合には期間満了となります。また、条件を満たした場合には代理人に対する特定の責任に対する補償の義務も含まれます。
役に立った
役に立たない
